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Abstract
Objective To assess the efficacy at 12 months of an early psychosocial
counselling and support programme for outpatients with mild Alzheimer’s
disease and their primary care givers.
Design Multicentre, randomised, controlled, rater blinded trial.
Setting Primary care and memory clinics in five Danish districts.
Participants 330 outpatients with mild Alzheimer’s disease and their
330 primary care givers.
Interventions Participating dyads (patient and primary care giver) were
randomised to control support during follow-up or to control support plus
DAISY intervention (multifaceted and semi-tailored counselling,
education, and support).
Main outcome measures Primary outcomes at 12 months for patients
were change from baseline in mini mental state examination (MMSE)
score, Cornell depression scale score, and proxy rated European quality
of life visual analogue scale (EQ-VAS) score. For care givers, outcomes
were change from baseline in geriatric depression scale (GDS 30 items)
score and EQ-VAS score.
Results Because of multiple testing, statistical significance was set at
an adjusted P limit of <0.0005. At 12 months there were no significant
differences between the two allocation groups in changes from baseline
in the primary and secondary outcomes. However, although
non-significant with the adjusted P limit, a small difference was observed
for one of the primary patient outcomes (Cornell depression scale score)
in patients in favour of the DAISY intervention group before and after
adjusting for attrition (P=0.0146 and P=0.0103 respectively).
Conclusions The multifaceted, semi-tailored intervention with
counselling, education, and support for patients with mild Alzheimer’s
disease and their care givers did not have any significant effect beyond
that with well structured follow-up support at 12 months after adjustment
for multiple comparisons. The small positive effect found in the
unadjusted primary outcome addressing depressive symptoms in patients
may call for further research focusing on patients with Alzheimer’s
disease and comorbid depression.
Trial registration ISRCTN74848736.
Introduction
Alzheimer’s disease is a common neurodegenerative disease
characterised by progressive decline in cognitive, social, and
occupational function, and often associated with affective
symptoms and behavioural disturbances.1 Alzheimer’s disease
accounts for 60-80% of all cases of dementia, and recent figures
indicate that as many as 35 million people worldwide have
dementia, which is projected to increase to 65 million within
the next two decades.2
Most patients with Alzheimer’s disease reside in the community
and require assistance and supervision from care givers. Being
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a family care giver for a patient with dementia is associated
with a greater risk of developing both somatic and psychiatric
health problems.3-5 Several studies have consistently shown that
counselling and psychosocial interventions for care givers may
have a significant positive effect in patients with moderate to
severe Alzheimer’s disease6-8 as well as in their care givers.6 9-18
However, in general the results have been inconsistent and the
quality of studies not optimal, and a need for appropriately
designed trials has been pointed out.19
With increased public awareness and better diagnostic methods,
patients with Alzheimer’s disease are now often diagnosed in
the early phase of their disease. Many patients with mild
dementia have some awareness of their own situation and may
request more attention and specific counselling programmes
directed towards their needs. Hence, there is a need to develop
and evaluate support programmes which focus specifically on
the needs of patients with mild dementia and their care givers
and which include psychosocial support for the patients as well
as for the care givers.
We hypothesised that a multifaceted and semi-tailored
intervention programme offered to patients and their primary
care givers during the first year after a diagnosis of Alzheimer’s
disease might prevent the emergence of depressive symptoms
and improve the quality of life of patients and care givers, and
perhaps even stabilise the patients’ cognitive function for some
time. Thus, our aimwith the Danish Alzheimer Study (DAISY)
was to investigate the efficacy of a multifaceted and
semi-tailored psychosocial counselling and support programme
offered to recently diagnosed patients with mild Alzheimer’s
disease and their primary care givers.
Methods
Study design
We carried out a randomised controlled trial allocating patients
with mild Alzheimer’s disease and their primary care giver
(proxy) to routine follow-up (controls, n=163) or to follow-up
supplemented with amultifaceted and semi-tailored intervention
(n=167) across five (out of 15) county districts in Denmark.
Before enrolment in the trial, both patients and proxies gave
written informed consent. The rationale, study design, and
baseline characteristics of the study have been reported in detail
previously20 and will be presented here briefly.
Eligibility criteria
Inclusion criteria for the patients were age ≥50 years, diagnosis
of Alzheimer’s disease within the past 12 months, mini mental
state examination (MMSE) score ≥20, and having a primary
care giver who was willing to participate in the study. A primary
care giver was defined as the informal care giver who was the
main person responsible for the informal care for the patient
and who had regular contact (at least weekly) with the patient.
All patients met the criteria for dementia according to the
Diagnostic and Statistical Manual of Mental Disorders (fourth
edition, DSM-IV)1 and the criteria for probable Alzheimer’s
disease according to the National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association
(NINCDS-ADRDA)21 or the McKeith criteria for Lewy body
dementia.22 Patients classified as having mixed Alzheimer’s
disease had probable Alzheimer’s disease plus minor vascular
changes visible on cranial computed tomography that could
contribute to the symptoms.
We excluded patients with severe somatic or psychiatric
comorbidity (including impaired hearing or vision) that would
substantially impair their cooperation in the intervention
programme, patients participating in other intervention studies,
and patients living in a nursing home at baseline.
All participants were followed for 12 months with assessment
of all outcomes at baseline and at six and 12 months by trained
raters. The raters were not informed of the patients’ allocation
status and did not perform more than one assessment visit for
each dyad of patient and care giver.
Control support during follow-up
At the assessments at six and 12 months, the raters were
instructed to accommodate the patient’s and carers’ typical
frustration and uncertainty associated with a recent diagnosis
by providing overall information and guidance, and they could
facilitate contact to relevant local support programmes in both
the control group and the intervention group.
Multifaceted and semi-tailored intervention
(DAISY intervention)
The DAISY intervention was conducted as a supplement to the
control support. It was designed with the objective of preventing
or reducing depressive symptoms, impairments of health related
quality of life, and loss of social network. It was tailored
individually to each of the participating dyads, and it offered
the participants a number of components at their disposal. The
intervention programme was conducted during the initial 8-12
months. The main components are described below; further
details are given in our previous paper.20
Counselling sessions—Up to seven counselling sessions were
scheduled: two sessions with the patient and care giver; two
sessions with the patient alone; two sessions with the care giver
alone; and an optional network session with the patient, care
giver, and family network. The general approach of the
counselling was based on constructivist principles23 and
supported by the use of a monitoring scheme, which was
established at the initial meeting and then used to focus
follow-up sessions in consensus with the ideas of Ishiayma.24
The principles and methods were anchored on the dynamics
that characterises the patient’s and care giver’s everyday life.
The counselling was based on a philosophical approach in which
each patient or care giver was given the possibility of expressing
his or her life story and what is of personal importance and of
great value. The counsellor offered the participants guidance
with common decision making, advice, and activities that help
the participants construct a meaningful life. Written notes were
used to focus follow-up sessions with the aim of improving
coping strategies and empowering the participants to focus on
the positive factors and resources in their lives, according to the
principles of self validation. A designated nurse undertook all
counselling sessions after having had special training in the
constructivist approach. Centres participating in the study
decided individually whether counselling was undertaken in the
patient’s home or at the centre.
Courses—Two parallel lines of five courses each were targeted
at patients and care givers respectively. The objective of the
courses was to provide a basic knowledge about the disease and
its consequences along with establishing a forum for patients’
and care givers’ exchange of experiences and coping strategies.
The courses for patients included information on key issues of
the disease and its consequences supported by printed handouts
with information on specific topics. The courses for care givers
included a more formalised education programme on
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Alzheimer’s disease, also supported by printed handouts with
information on specific topics. The two course lines were each
scheduled for 12 participants per session being run by one
counsellor and one invited teacher. All courses were planned
to last two hours. A full intervention was defined when patients
and care givers participated in three or more counselling sessions
and three or more courses.
Additional intervention—During the intervention period the
study coordinator contacted the participants by telephone about
five to eight times at three or four weeks intervals. The calls
focused on issues discussed at the individual sessions and
education courses, but sometimes the conversations included
other issues relevant for the individual participant. Patients and
care givers were also supplied with comprehensive written
information to support the information given at counselling
sessions and courses and a log book in which they could write
information and thoughts about their daily life.
Study outcomes
This study is to be considered as an exploratory randomised
controlled trial since we could not identify similar studies. Thus,
we operated with three primary outcomes for the patient and
two primary outcomes for the principal care giver at 12 months.
Primary outcomes for patients were change from baseline in
mini mental state examination (MMSE) score, Cornell
depression scale score, and proxy rated quality of life (EQ-VAS)
score. For care givers, outcomes were change from baseline in
geriatric depression scale (GDS 30 items) score and EQ-VAS
score.
Primary outcomes for patients:
1. Mini mental state examination (MMSE)25—This includes
11 items focusing on cognitive aspects of mental functions.
The score ranges from 0 to 30, with higher scores indicating
better cognitive performance. In the DAISY study all patients
had a MMSE score ≥20 at baseline in order to comply with
the inclusion criteria.
2. Cornell depression scale for dementia26—Based on
impressions from interviews with both patient and care giver,
the interviewing clinicians rated depressive symptoms in the
patients according to the scale. The scale consists of 19 items
that each ranges from 0 (no problems) to 2 (severe problems).
Thus, the total score ranges from 0 to 38, with higher values
indicating more depressive symptoms.
3. European quality of life visual analogue scale (EQ-VAS)
proxy rated27—The care givers completed the Danish
validated version of EQ-5D, rating their impression of the
patient’s health related quality of life.28 We used the VAS
subscale, which ranges from 0 to 100 with higher values
indicating better quality of life as outcome.
Primary outcomes for principal care givers:
1. Geriatric depression scale (GDS)29—The care givers
completed the Danish validated version of the GDS, with
30 items. One point is assigned to each answer and
corresponds to a scoring grid. A score of 10 or 11 is the usual
threshold to separate depressed from non-depressed
individuals.
2. EQ-VAS27—The care givers completed the Danish
validated version of EQ-5D rating their impression of their
own health related quality of life.28 We used the VAS
subscale.
This study also included five secondary outcomes: EQ-VAS
(patient rated),27 quality of life scale for Alzheimer’s disease
(QoL-AD) (both patient and proxy rated),30 the neuropsychiatric
inventory questionnaire (NPI-Q),31 and the Alzheimer’s Disease
Cooperative Study activities of daily living scale (ADSC-ADL)32
for clinical trials in Alzheimer’s disease (table 1⇓).
Sample size
Based onmean scores and score variations forMMSE, EQ-VAS,
Cornell depression scale, and GDS from previous studies in
similar populations with Alzheimer’s disease,13 33-35we estimated
that a group size of 165 was needed in order to detect a
minimum effect size (defined as the difference at 12 months
between groups for observed scores) of 1.2 (SD 2.6) forMMSE,
2.0 (4.4.) for Cornell depression scale, 1.8 (4.9) for GDS, and
6.0 (15) for EQ-VAS with a type I error of 5% and type II error
of 10%, based on an individual analysis for each presented test.
The calculations were based on a drop-out rate of 20% at 12
months. The minimum effect sizes were defined from outcomes
in previous intervention studies.13 34 35
Randomisation
The randomisation was done with Stat Direct version 2.3.7. We
used a random block size algorithm to prevent imbalance
between the allocation groups. Patients were stratified by
treatment centre, MMSE score, and use of antidementia drugs.
The allocation procedure was concealed for the DAISY project
group and was conducted by an independent department in
Rigshospitalet. At enrolment, a fax was sent to this department
together with a participant code and information regarding
stratification. Then the stratification was conducted, and the
DAISY group received a fax with information regarding
allocation status. The allocation code was concealed for the
raters at follow-up visits and each rater could not rate a dyad
more than once.
Statistics
Comparisons of patient and care giver sociodemographic
characteristics and outcome measures at baseline between
randomisation groups were done by Student’s t tests for
continuous variables and χ2 tests for categorical variables. At
the six and 12 month follow-ups, the outcomes in the two
randomisation groups were summarised by mean and standard
deviation (SD); direct comparison between groups was done by
t tests. To account for baseline score, we conducted an analysis
of covariance, a multivariate regression relating outcome to
randomisation and the baseline value of the outcome36 using
generalised estimating equations to account for clustering within
centres. For the comparison of baseline values, dyads with
missing values were omitted. Difference in mortality between
the randomisation groups was evaluated by a hazard ratio from
a Cox regression model.
In further analyses, we compared the development in the
outcomes between randomisation groups and analysed this with
linear models using generalised estimating equations to account
for repeated measurements; the inclusion of a categorical centre
indicator variable accounts for possible clustering by treating
centre. Differential dropout from the study may cause bias, as
the dyads with disadvantageous outcomes tend to drop out,
artificially favouring the group with highest dropout rate. To
adjust for such bias, the measurements that were available at
the six and 12 month follow-up were weighted by the inverse
of an estimate of the probability of staying in the study.37 These
probabilities were estimated from the data in a logistic regression
model with the dyad’s characteristics and the observed outcomes
from previous visits as covariates.
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To adjust for multiple testing, the significance level was set to
control for the false discovery rate at 5% by the procedure of
Benjamini-Hochberg.38 All analyses were done in the intention
to treat population—that is, dyads were analysed according to
randomisation group regardless of compliance.
Results
Characteristics of participants
We screened 558 patients for eligibility and randomised 330
dyads into either DAISY intervention or control support only
(figure⇓). Demographics, clinical characteristics, and outcomes
at baseline, stratified by allocation groups, are presented in table
1⇓. The randomisation balanced demographics and primary
outcomes. However, an imbalance in favour of the control group
was observed in two secondary patient outcomes for quality of
life—patient rated EQ-5D VAS (P=0.0061) and proxy rated
QoL-AD (P=0.0169).
The mean ages of patients and care givers were 76.2 years and
66.0 years, respectively. For patients, mean baseline mental
state (MMSE) score was 24.1, Cornell depression scale 4.8, and
proxy-rated quality of life (EQ-VAS) 63.5. For care givers,
mean baseline geriatric depression scale score was 4.7 and
EQ-VAS 80.4.
A total of 276 (84%) dyads completed the 12 month follow-up
assessment (figure⇓). At 12 months, a total of 32 dyads were
lost to follow-up in the DAISY intervention group compared
with 22 in the control group. In the intervention group 10 died
during the 12 months, compared with three in the control group
(hazard ratio 3.15 (95% confidence interval 0.9 to 11.6),
P=0.09).
Intervention
Of the 163 dyads allocated to the DAISY intervention, 157
received the intervention, three dropped out because of the
intervention being too demanding for care givers, one dropped
out because the intervention was too demanding for the patient,
one dropped out because the patient was hospitalised, and one
dropped out because the patient died before the intervention
started. Table 2⇓ shows the participation rate in the individual
components of the DAISY intervention. A total of 118 (72%)
in the DAISY intervention group completed the full intervention
according to our definition.
Efficacy
Tables 3⇓ and 4⇓ present the results for primary and secondary
outcomes at six and 12 months (adjusted for attrition). Because
of multiple testing, differences with P<0.0005 were determined
to be statistically significant. None of the primary and secondary
outcomes was significantly different in the two groups. At 12
months, change from baseline for one of the primary patient
outcomes, Cornell depression scale score, indicated a small
difference in favour of the intervention group (P=0.0146), and
this difference remained after adjustment for attrition (P=0.0103)
(table 4⇓) but not significant when applying the P limit corrected
for multiple testing.
Discussion
Principal findings
To our knowledge this is the largest randomised study conducted
in patients with mild Alzheimer’s disease and their primary care
givers to evaluate the effect of a multifaceted and semi-tailored
psychosocial support programme. The main result was that,
after adjustment for multiple comparisons, the addition of the
DAISY intervention programme to structured follow-up did not
have any significant effect on outcome in patients or care givers.
Strengths of the study
A recent systematic Cochrane review and meta-analysis called
for new randomised controlled studies with adequate
randomisation, concealment of allocation, a priori sample size
calculations, and adequate rater blinding for studies directed
towards patients with mild dementia.39 40 The DAISY study met
all quality criteria established by the Cochrane group.
We included only patients with recently diagnosed mild
dementia who had been offered a conventional diagnostic
evaluation by a local specialist in dementia. By requiring
appropriate diagnostic evaluation, wewanted to exclude patients
with questionable dementia and non-progressive cognitive
disorders. Patients with frontotemporal dementia were not
eligible for our study, as they often have other needs, they might
have had difficulties in cooperating to the programme, and it
may have been difficult to mix patients with different disorders
in the same counselling sessions.
There is a risk that important aspects of supportive interventions,
such as perceptions and attitudes concerning the programme or
staff members, adverse effects, or the positive aspects of sharing
experiences with others, could be overlooked in quantitatively
designed studies. Therefore, qualitative studies are also needed,
and these may help design future quantitative studies.41 42 A
qualitative study was done in a subgroup of DAISY participants.
This study concluded that early tailored counselling and support
may improve patients’ and care givers’ opportunities to adapt
to the challenges of Alzheimer’s disease and to maintain
wellbeing.42
The aim of the DAISY intervention was to prevent the
emergence of depressive symptoms and impairment of health
related quality of life in patients and in their care givers, and
perhaps even stabilise the patients’ functional status for some
time. The programme comprised counselling, information, and
support to patients and their primary care givers during the
initial months after a diagnosis of Alzheimer’s disease had been
established. Rather than focusing on compensation for lost
functional abilities, the philosophy of the counselling programme
was to focus on positive resources, intact functions and retained
skills, and activities that patients could still take part in. A
unique feature of the programmewas the twin-track design with
activities and information specifically directed towards the
patients and towards the care givers. Another unique feature
was the semi-tailored design, with some components tailored
for the needs of an individual patient or care giver and with
other components common for all participants. The inclusion
of the family network in one of the counselling sessions, at the
discretion of the patient, was meant to ensure information was
available to all, to prevent stigmatisation, to identify important
resources in the network, and to enable the care giver to recruit
a larger network when needed.
An additional feature of the DAISY study is the potential for
follow-up of the cohort far beyond the period of the study visits
by using information in the systematic and comprehensive
Danish healthcare registries.
Limitations of the study
Patients and care givers were invited to the study regardless of
their expected or expressed needs for intervention. Thus,
inclusion into the study was not restricted to patients and care
givers actively seeking help. The logistics for participation in
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the study programme was quite demanding, particularly for
those in the DAISY intervention group. Adherence to the many
counselling meetings and courses may be difficult for some,
particularly for those with impaired somatic health status, with
busy care givers, or living far away from the study centre.
By the fact that a diagnosis and a care giver were required for
entering the study, our population was selected. However, based
on the reported baseline characteristics and on previously
reported data on self rated health and social performance, the
profile of patients and care givers in our study was similar to
that of patients included in typical drug trials and other clinical
cohort studies in mild Alzheimer’s disease.34 35 43 It is possible
that a more positive effect could have been observed if we had
limited inclusion of patients and care givers to those actively
seeking help or living near the counselling site, measures which
might have reduced the dropout rate. On the other hand, the
patient group was selected with a relatively high representation
of patients with a supportive social network, and may not
adequately reflect the average population of Alzheimer’s disease
patients.
Although the intervention was semi-tailored to the needs of
individual patients, a more individualised counselling and
teaching programme might well have been more beneficial.
Because there is no established consensus on primary outcomes
in studies of psychosocial interventions for patients with mild
dementia, the study was to some extent explorative and will
contribute to the design of future studies.
Furthermore, there was little guidance from the literature for
the selection of primary outcome parameters and for a priori
sample size calculations. Our selection of primary efficacy
measures was based on the objectives of the DAISY
intervention, on results studies of psychosocial interventions
for care givers to patients with more advanced dementia, and
on drug trials in mild Alzheimer’s disease. We only used
validated questionnaires as primary and secondary outcomes.
The association between patient and proxy rated quality of life
even in mild Alzheimer’s disease is complex. Many studies
have found a significant discrepancy between these measures,
which to some degree may be explained by anosognosia.44
Because long term follow-up was planned, proxy rated quality
of life was preferred as the main outcome, although patient rated
data were also recorded. The range of primary outcomes in the
DAISY study underscores the explorative nature of the study.
It also underscores the notion that the use of statistical
significance to determine on which outcomes DAISY
interventionmay have optimal effect may overstate the evidence,
because of the many related comparisons that are performed.
In our power calculation we did not adjust for multiple primary
outcomes or for multiple time points, indicating that the DAISY
studywas perhaps underpowered, although still the largest single
randomised controlled trial of psychosocial intervention
undertaken in patients with mild Alzheimer’s disease and their
primary care givers.
For ethical reasons and in order not to leave any participants in
the control group without any intervention except blinded rating,
both groups received a standardised structured follow-up
intervention. Therefore, the attempts to provide equal treatment
of both intervention and control participants in all respects other
than the DAISY intervention left all participants with a service
well above the level of usual care for patients with dementia in
Denmark.45 46 Thus, comparing the follow-up intervention with
the DAISY intervention may havemasked the potential efficacy
of the DAISY intervention.
Comparisonswith other studies andmeaning
of the study
In contrast to the DAISY study, most previous studies have
investigated the efficacy of psychosocial support aimed at care
givers and not at dyads. An innovative US study demonstrated
sustained benefits in reducing depressive symptoms in care
givers for spouses with mild to severe Alzheimer’s disease with
an intervention consisting of counselling and support aimed at
the care giver.13 In a recent systematic review assessing the
effectiveness of interventions based on information and support
for informal care givers of people with dementia in community
settings, 44 randomised studies were included according to
quality and relevance.19 Overall the methodological quality of
the studies was poor. For instance, only four of the studies
included an adequate randomisation process and concealment
of allocation, and a priori sample size calculations were rare.
Only a few studies were blinded. Most of the studies had a
maximum follow-up period of 12 months, and many reported
only the positive results. The reviewers concluded that the lack
of adherence to best practice in trial based studies on
effectiveness was overwhelming. In general, there was a
significant but very small overall effect on depressive symptoms
in the care givers, which should be interpreted with caution.
The meta-analysis did not identify any significant effect in other
outcome parameters. The authors concluded that there is a
pressing need to ensure that supportive interventions at the
development stage are accompanied by good quality randomised
evaluation in which outcomes that are important for clinicians
and carers are measured. Subsequently, at least one recent RCT
on psychosocial intervention for family carers was unable to
identify any effect on the primary outcome variable.3 We have
not identified any previous RCTs on psycho-social interventions
for patients with mild Alzheimer’s disease.
While our method of allocation met the quality standard and
balanced dyads’ characteristics and most outcomes at baseline,
we observed an imbalance at baseline in favour of the control
group on two secondary outcomes—EQ-VAS (patient rated)
and QoL-AD (proxy rated) (tables 1⇓ and 4⇓). This underlines
the importance of defining the outcomes as difference from
baseline rather than observed scores. Furthermore, the slightly
higher mortality in the DAISY intervention group may reflect
the imbalances at baseline in favour of the control group..
Unanswered questions and future research
This study focused on both patients with mild Alzheimer’s
disease and their care givers irrespective of whether they were
actively seeking help. We propose further research on
interventions aimed specifically at dyads with an expressed need
for help and with focus on depressive symptoms.
Conclusions
The multifaceted semi-tailored intervention programme with
counselling, education, and support for patients with mild
Alzheimer’s disease and their care givers did not have any
significant effect above that of well structured support (control)
on primary outcomes at 12 months after adjustment for multiple
comparisons. The small positive difference between allocation
groups for depressive symptoms in patients (although not
significant when adjusting P values for multiple comparisons)
may call for further research focusing on patients with
Alzheimer’s disease and comorbid depression. Furthermore,
future studies of intensive psychosocial intervention programmes
in mild Alzheimer’s disease may benefit from focusing on
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patients and care givers who express a need for help and support,
rather than on unselected patients.
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Tables
Table 1| Baseline characteristics of patients with Alzheimer’s disease and their care givers who participated in the Danish Alzheimer
Intervention Study (DAISY). Values are numbers (percentages) of participants unless stated otherwise
Control (n=167)Intervention (n=163)
Patient characteristics
Sex (n=163):
75 (45)76 (47)Male
92 (55)87 (53)Female
75.9 (6.6)76.5 (7.7)Mean (SD) age (years)
Household status:
48 (29)54 (33)Living alone
119 (71)109 (67)Living with others
Home:
56 (33.5)66 (40.5)Rented
111 (66.5)97 (59.5)Owned
Education:
57 (34.1)60 (36.8)None
49 (29.3)39 (23.9)<3 years
61 (36.5)64 (39.3)≥3 years
Charlson comorbidity index:
73 (43.7)64 (39.3)No comorbidity
65 (38.9)75 (46.0)1 comorbidity
29 (17.4)24 (14.7)≥2 comorbidities
Diagnosis:
127 (76.1)112 (68.7)Pure Alzheimer’s disease
38 (22.8)44 (27.0)Mixed Alzheimer’s disease and vascular dementia
2 (1.2)7 (4.3)Lewy body dementia
Caregiver characteristics
Sex:
56 (33.5)54 (33.1)Male
111 (66.5)109 (66.9)Female
66.5 (12.7)65.5 (12.7)Mean (SD) age (years)
Relation:
111 (66.5)104 (63.8)Spouse
41 (24.5)45 (27.6)Child or child in law
15 (9.0)14 (8.6)Other
Lives with patient:
112/166 (67.5)101/162 (62.4)Yes
54/166 (32.5)61/162 (37.6)No
Home:
45 (26.9)45 (27.6)Rented
122 (73.1)118 (72.4)Owned
Education:
37/166 (22.3)41 (25.2)None
63/166 (37.9)46 (28.2)<3 years
66/166 (39.8)76 (46.6)≥3 years
Outcome measures
Primary patient outcomes:
24.1 (2.7)24.0 (2.5)Mean (SD) MMSE
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Table 1 (continued)
Control (n=167)Intervention (n=163)
4.41 (4.0)5.17 (4.8)Mean (SD) Cornell depression scale
64.7 (20.4)62.1 (18.4)
(n=162)
Mean (SD) EQ-VAS (proxy rated)
Primary caregiver outcomes:
81.4 (16.3)79.3 (16.3)
(n=162)
Mean (SD) EQ-VAS
4.71 (5.02)4.74 (5.16)
(n=162)
Mean (SD) GDS
Secondary patient outcomes:
78.8 (16.5)73.6 (17.1)
(n=161)
Mean (SD) EQ-VAS (patient rated)
39.5 (5.7)38.8 (6.0)Mean (SD) QoL-AD (patient rated)
34.7 (6.6)33.0 (6.1)Mean (SD) QoL-AD (proxy rated)
3.90 (3.65)3.90 (3.61)Mean (SD) NPI-Q
61.8 (11.4)61.2 (11.4)Mean (SD) ADSC-ADL
MMSE=mini mental state examination. EQ-VAS=European quality of life visual analogue scale. GDS=geriatric depression scale. QoL-AD=quality of life scale for
Alzheimer’s disease. NPI-Q=neuropsychiatric inventory questionnaire. ADSC-ADL=Alzheimer’s Disease Cooperative Study activities of daily living scale.
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Table 2| Rates of participation in the components of the DAISY (Danish Alzheimer Intervention Study) intervention among the patients with
Alzheimer’s disease and their care givers who were allocated to the intervention. Values are fractions (95% CI) of potential participants
Care giver (n=157)Patient (n=157)Component
Constructivist counselling:
0.99 (0.98 to 1.00)1.00Initial meeting
0.85 (0.79 to 0.92)0.84 (0.78 to 0.90)1st follow-up meeting
0.78 (0.72 to 0.85)0.78 (0.72 to 0.85)2nd follow-up meeting
0.32 (0.25 to 0.40)0.32 (0.25 to 0.39)Network meeting*
0.82 (0.76 to 0.87)0.83 (0.78 to 0.89)Final meeting
0.80 (0.73 to 0.86)0.36 (0.28 to 0.43)Telephone counselling†
Courses:
0.83 (0.77 to 0.89)0.84 (0.78 to 0.90)1st session
0.82 (0.76 to 0.88)0.83 (0.77 to 0.89)2nd session
0.77 (0.70 to 0.84)0.76 (0.70 to 0.83)3rd session
0.75 (0.68 to 0.82)0.76 (0.70 to 0.83)4th session
0.74 (0.66 to 0.80)0.76 (0.70 to 0.83)5th session
Overall participation‡:
0.91 (0.87 to 0.96)0.88 (0.83 to 0.93)Participated in ≥3 counsellings
0.80 (0.74 to 0.87)0.81 (0.75 to 0.87)Participated in ≥3 courses
Participation in individual meetings and sessions was determined by individual needs and preferences, which were assessed by the counsellor and participant in
collaboration. Target rates were thus not necessarily 1.00, and for that reason the conventional terminology of compliance is avoided.
*A network comprised one to four people but is considered here as one unit. Except for the network meetings, networks were not invited to attend counselling or
courses; some participated in selected sessions, however.
†The patient or caregiver, or both, could register for calls.
‡Participation in three sessions of constructivist counselling (of which at least two were face to face, not by telephone) or courses was considered a high degree
of concordance, given the flexible nature of the intervention.
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Table 3| Effect of the DAISY (Danish Alzheimer Intervention Study) intervention compared with control support among patients with
Alzheimer’s disease and their care givers on the primary and secondary outcomes and the difference of these outcomes from baseline.
Missing values are omitted from these intention to treat analyses. Values are means (standard deviations) unless stated otherwise
Difference in scores, intervention v
controlMean change from baselineObserved scores
P value of t test†
Mean (95%
CI)*
P value of
t test†ControlIntervention
P value of
t test†ControlIntervention
Follow-up at 6 months
Primary patient
outcomes:
0.71240.12 (−0.48 to
0.71)
0.6741−1.18 (2.93)
(n=149)
−1.03 (3.29)
(n=144)
0.912723.0 (3.6)
(n=149)
23.0 (3.8)
(n=144)
MMSE
0.81300.14 (−0.99 to
1.27)
0.85371.19 (4.46)
(n=150)
1.09 (4.30)
(n=142)
0.41715.59 (4.60)
(n=150)
6.04 (4.81)
(n=142)
Cornell
depression scale
0.23590.62 (−0.41 to
1.66)
0.4024−3.52 (17.3)
(n=150)
−1.70 (19.4)
(n=139)
0.676761.3 (20.6)
(n=150)
60.3 (20.2)
(n=140)
EQ VAS (proxy
rated)
Primary care
giver outcomes:
0.00572.61 (0.76 to
4.46)
0.0673−1.25 (14.3)
(n=150)
2.07 (16.3)
(n=140)
0.508380.3 (18.2)
(n=150)
81.6 (16.4)
(n=141)
EQ VAS
0.0184−0.39 (−0.72
to −0.07)
0.38680.81 (3.91)
(n=150)
0.43 (3.51)
(n=140)
0.52125.38 (5.77)
(n=150)
4.97 (5.06)
(n=141)
GDS
Secondary
patient
outcomes:
0.41421.51 (−2.11 to
5.13)
0.0930−2.06 (18.5)
(n=147)
1.54 (17.6)
(n=140)
0.864776.3 (18.2)
(n=147)
75.9 (17.4)
(n=141)
EQ VAS
(patient rated)
0.1822−0.52 (−1.28
to 0.24)
0.5347−0.26 (5.36)
(n=149)
−0.63 (5.01)
(n=144)
0.245039.2 (6.6)
(n=149)
38.3 (6.4)
(n=144)
QoL-AD
(patient rated)
0.06800.68 (−0.05 to
1.41)
0.0518−1.55 (4.71)
(n=149)
−0.44 (4.91)
(n=142)
0.556933.2 (6.7)
(n=149)
32.8 (6.3)
(n=142)
QoL-AD (proxy
rated)
0.11510.21 (−0.05 to
0.48)
0.55280.60 (3.32)
(n=150)
0.85 (3.84)
(n=141)
0.78294.45 (4.24)
(n=150)
4.59 (4.12)
(n=141)
NPI-Q
0.0148−2.19 (−3.96
to −0.43)
0.0467−1.28 (9.0)
(n=150)
−3.43 (9.3)
(n=141)
0.113860.5 (13.5)
(n=150)
58.0 (13.4)
(n=141)
ADSC-ADL
Follow-up at 12 months
Primary patient
outcomes
0.06050.50 (−0.02 to 1.02)0.2515−1.96 (4.13)
(n=139)
−1.44 (3.22)
(n=130)
0.526122.2 (4.8)
(n=139)
22.5 (3.9)
(n=130)
MMSE
0.0146−0.81 (−1.46 to −0.16)0.13361.31 (5.23)
(n=141)
0.40 (4.71)
(n=130)
0.22285.77 (5.07)
(n=141)
5.05 (4.61)
(n=130)
Cornell
depression scale
0.31771.97 (−1.89 to 5.82)0.2529−6.91 (16.9)
(n=143)
−4.30 (20.0)
(n=128)
0.753457.4 (22.5)
(n=143)
58.2 (18.8)
(n=129)
EQ VAS (proxy
rated)
Primary
caregiver
outcomes:
0.2218−0.65 (−1.70 to 0.39)0.8358−0.38 (14.5)
(n=144)
0.02 (16.3)
(n=128)
0.239981.8 (17.0)
(n=144)
79.5 (16.0)
(n=129)
EQ VAS
0.11190.91 (−0.21 to 2.03)0.07800.20 (4.27)
(n=143)
1.16 (4.59)
(n=128)
0.22864.82 (5.70)
(n=143)
5.64 (5.45)
(n=129)
GDS
Secondary
patient
outcomes:
0.07951.70 (−0.20 to 3.60)0.1057−3.47 (18.0)
(n=132)
0.06 (16.7)
(n=125)
0.788775.5 (17.8)
(n=132)
74.9 (18.2)
(n=126)
EQ VAS
(patient rated)
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Table 3 (continued)
Difference in scores, intervention v
controlMean change from baselineObserved scores
P value of t test†
Mean (95%
CI)*
P value of
t test†ControlIntervention
P value of
t test†ControlIntervention
0.8842−0.08 (−1.17 to 1.01)0.9722−0.89 (5.64)
(n=140)
−0.91 (4.61)
(n=129)
0.718438.2 (6.8)
(n=140)
38.2 (6.6)
(n=129)
QoL-AD
(patient rated)
0.05341.33 (−0.019 to 2.69)0.0040−2.44 (5.24)
(n=144)
−0.70 (4.64)
(n=130)
0.612832.2 (6.7)
(n=144)
32.6 (6.2)
(n=130)
QoL-AD (proxy
rated)
0.17330.63 (−0.28 to 1.55)0.14240.33 (3.91)
(n=143)
1.02 (3.84)
(n=129)
0.26694.24 (4.36)
(n=143)
4.79 (3.82)
(n=129)
NPI-Q
0.7097−0.52 (−3.26 to 2.22)0.6851−5.64 (12.6)
(n=143)
−6.21 (10.3)
(n=130)
0.534156.6 (17.8)
(n=143)
55.3 (15.1)
(n=130)
ADSC-ADL
MMSE=mini mental state examination. EQ-VAS=European quality of life visual analogue scale. GDS=geriatric depression scale. QoL-AD=quality of life scale for
Alzheimer’s disease. NPI-Q=neuropsychiatric inventory questionnaire. ADSC-ADL=Alzheimer’s Disease Cooperative Study activities of daily living scale.
*The mean difference in outcome attributable to the randomisation is assessed in an analysis of covariance where the primary comparison between randomisation
groups is adjusted for the baseline value of the corresponding outcome (and thereby is the same as the mean difference in change from baseline); the confidence
intervals (95% CI) and P values corresponding to these differences are calculated using generalised estimating equations to account for correlation within treating
centre.
†To control the false discovery rate at 5%, a P value of 0.0005 is considered significant.
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Table 4| Longitudinal effect of the DAISY (Danish Alzheimer Intervention Study) intervention compared with control support among patients
with Alzheimer’s disease and their care givers on the primary and secondary outcomes and the difference of these outcomes from baseline
(intention to treat analyses). Values are means (95% CI) unless stated otherwise*
Mean change from baselineObserved scores
P value of t
test†ControlIntervention
P value of t
test†ControlIntervention
Follow-up at 6 months
Primary patient
outcomes:
0.8055−1.08 (−1.58 to −0.58)−1.17 (−1.76 to −0.59)0.754523.0 (22.4 to 23.6)22.9 (22.2 to 23.5)MMSE
0.46021.23 (0.50 to 1.96)0.85 (0.11 to 1.60)0.51765.64 (4.86 to 6.71)6.03 (5.23 to 6.82)Cornell depression
scale
0.5563−3.56 (−6.45 to −0.68)−2.37 (−5.56 to 0.82)0.595161.1 (57.8 to 64.5)59.8 (56.4 to 63.1)EQ VAS (proxy rated)
Primary care giver
outcomes:
0.0758−1.00 (−3.30 to 1.30)2.18 (−0.54 to 4.90)0.576580.4 (77.5 to 83.3)81.4 (78.7 to 84.2)EQ VAS
0.46170.85 (0.11 to 1.58)0.44 (−0.29 to 1.16)0.61875.55 (4.56 to 6.55)5.18 (4.68 to 6.12)GDS
Secondary patient
outcomes:
0.0268−2.54 (−5.50 to 0.43)2.21 (−0.71 to 5.13)0.839476.2 (73.4 to 79.1)75.8 (73.0 to 78.7)EQ VAS (patient rated)
0.8875−0.43 (−1.34 to 0.49)−0.52 (−0.37 to 0.34)0.285439.1 (38.0 to 40.1)38.3 (37.2 to 39.3)QoL-AD (patient rated)
0.0312−1.70 (−2.51 to −0.88)−0.38 (−1.24 to 0.48)0.613833.0 (32.0 to 34.1)32.6 (31.6 to 33.7)QoL-AD (proxy rated)
0.87790.72 (0.15 to 1.29)0.78 (0.10 to 1.47)0.89454.63 (3.91 to 5.34)4.68 (3.98 to 5.39)NPI-Q
0.0964−1.34 (−2.98 to 0.30)−3.27 (−4.99 to −1.55)0.112860.4 (58.1 to 62.7)58.0 (55.7 to 60.2)ADSC-ADL
Follow-up at 12 months
Primary patient
outcomes:
0.6502−1.80 (−2.56 to −1.04)−1.55 (−2.19 to −0.91)0.729422.3 (21.5 to 23.1)22.5 (21.8 to 23.2)MMSE
0.01031.38 (0.49 to 2.27)−0.20 (−1.04 to 0.64)0.16115.79 (4.86 to 6.71)4.97 (4.20 to 5.74)Cornell depression
scale
0.2308−6.83 (−10.10 to
−3.56)
−3.88 (−7.38 to −0.37)0.879857.9 (54.0 to 61.8)58.3 (54.8 to 61.7)EQ VAS (proxy rated)
Primary care giver
outcomes:
0.77990.20 (−2.31 to 2.71)−0.31 (−3.41 to 2.79)0.203481.6 (78.8 to 84.5)79.0 (76.0 to 81.9)EQ VAS
0.25000.26 (−0.51 to 1.03)0.96 (0.05 to 1.86)0.30644.97 (3.97 to 5.97)5.70 (4.68 to 6.72)GDS
Secondary patient
outcomes:
0.0667−4.20 (−8.29 to −0.11)0.73 (−2.41 to 3.88)0.925474.6 (70.5 to 78.7)74.4 (71.1 to 77.6)EQ VAS (patient rated)
0.7213−1.04 (−2.04 to −0.04)−0.82 (−1.77 to 0.12)0.581238.5 (37.3 to 39.6)38.0 (36.8 to 39.2)QoL-AD (patient rated)
0.0013−2.61 (−3.58 to −1.64)−0.47 (−1.35 to 0.41)0.573232.1 (31.0 to 33.2)32.6 (31.4 to 33.7)QoL-AD (proxy rated)
0.40450.43 (−0.26 to 1.13)0.85 (0.16 to 1.53)0.42734.34 (3.56 to 5.11)4.75 (4.09 to 5.41)NPI-Q
0.2689−4.63 (−6.92 to −2.35)−6.39 (−8.51 to −4.27)0.254957.1 (54.2 to 60.0)54.8 (52.1 to 57.6)ADSC-ADL
MMSE=mini mental state examination. EQ-VAS=European quality of life visual analogue scale. GDS=geriatric depression scale. QoL-AD=quality of life scale for
Alzheimer’s disease. NPI-Q=neuropsychiatric inventory questionnaire. ADSC-ADL=Alzheimer’s Disease Cooperative Study activities of daily living scale.
*Means are estimated from a longitudinal model where selective dropout is accounted for by inverse proportional weighting; the inclusion of a categorical indicator
variable for treating centre accounts for possible clustering within centre; confidence intervals and P values are calculated with generalised estimating equations.
†To control the false discovery rate at 5%, a P value of 0.0005 is considered significant.
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Figure
Flow of participants through Danish Alzheimer Intervention Study (DAISY)
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